News

The transaction, which has been unanimously approved by Boards of Directors from both companies, will strengthen Alexion’s business in developing and commercializing transformative therapies for patients with devastating

According to the company, the decision taken to retain existing holding in ViiV Healthcare reflects on its updated strong positive outlook. ViiV Healthcare, is a joint venture with

The world market for HAE reached $1.1bn in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art

Upon issuance, the patent will provide additional intellectual property protection for MANF (mesencephalic-astrocyte-derived neurotrophic factor) protein therapy and cell therapy. The allowed patent claims cover compositions of matter

The Company’s Phase 3 protocol provides for a 25-week study with 300 HIV patients, which could start as early as 30 days after submission. The Company believes that

Results showed HUMIRA significantly lowered their risk of uncontrolled uveitis or vision loss. The results were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2015

PKAN is believed to affect about one to three persons per million worldwide and there are currently no approved treatment available. The company has started the screening of

AATD is a rare genetic disorder that can severely damage the liver and lungs of affected individuals. The trial will start dose escalation in healthy volunteers (Part A)